TAK-828F   Click here for help

GtoPdb Ligand ID: 9867

Synonyms: compound 10 [PMID: 29510038] | TAK-828 | TAK828F
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: TAK-828F is a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist [6,12]. The X-ray structure of RORγt in complex with TAK-828F has been submitted to the Protein Data Bank (6BR3).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 108.83
Molecular weight 509.23
XLogP 3.23
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc2c(n1)CCN(C2C(=O)Nc1cc(F)c2c(c1)CCC2(C)C)C(=O)C1CC(C1)CC(=O)O
Isomeric SMILES COc1ccc2c(n1)CCN([C@H]2C(=O)Nc1cc(F)c2c(c1)CCC2(C)C)C(=O)[C@@H]1C[C@@H](C1)CC(=O)O
InChI InChI=1S/C28H32FN3O5/c1-28(2)8-6-16-13-18(14-20(29)24(16)28)30-26(35)25-19-4-5-22(37-3)31-21(19)7-9-32(25)27(36)17-10-15(11-17)12-23(33)34/h4-5,13-15,17,25H,6-12H2,1-3H3,(H,30,35)(H,33,34)/t15-,17+,25-/m1/s1
InChI Key ICMFYVOUDGRBLG-VFHHBZAHSA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 1 safety, tolerability and PK/PD evaluation trial of TAK-828F in healthy subjects (NCT02817516) was terminated early.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02817516 A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants Phase 1 Interventional Takeda